Sentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized SERC trial
Abstract Based on results of clinical trials, completion ALND (cALND) is frequently not performed for patients with breast conservation therapy and one or two involved sentinel nodes (SN) by micro- or macro-metastases. However, there were limitations despite a conclusion of non-inferiority for cALND...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/c13f72211bf3423f91ce4844474dd13c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:c13f72211bf3423f91ce4844474dd13c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:c13f72211bf3423f91ce4844474dd13c2021-12-02T18:01:52ZSentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized SERC trial10.1038/s41523-021-00336-32374-4677https://doaj.org/article/c13f72211bf3423f91ce4844474dd13c2021-10-01T00:00:00Zhttps://doi.org/10.1038/s41523-021-00336-3https://doaj.org/toc/2374-4677Abstract Based on results of clinical trials, completion ALND (cALND) is frequently not performed for patients with breast conservation therapy and one or two involved sentinel nodes (SN) by micro- or macro-metastases. However, there were limitations despite a conclusion of non-inferiority for cALND omission. No trial had included patients with SN macro-metastases and total mastectomy or with >2 SN macro-metastases. The aim of the study was too analyze treatment delivered and pathologic results of patients included in SERC trial. SERC trial is a multicenter randomized non-inferiority phase-3 trial comparing no cALND with cALND in cT0-1-2, cN0 patients with SN ITC (isolated tumor cells) or micro-metastases or macro-metastases, mastectomy or breast conservative surgery. We randomized 1855 patients, 929 to receive cALND and 926 SLNB alone. No significant differences in patient’s and tumor characteristics, type of surgery, and adjuvant chemotherapy (AC) were observed between the two arms. Rates of involved SN nodes by ITC, micro-metastases, and macro-metastases were 5.91%, 28.12%, and 65.97%, respectively, without significant difference between two arms for all criteria. In multivariate analysis, two factors were associated with higher positive non-SN rate: no AC versus AC administered after ALND (OR = 3.32, p < 0.0001) and >2 involved SN versus ≤2 (OR = 3.45, p = 0.0258). Crude rates of positive NSN were 17.62% (74/420) and 26.45% (73/276) for patient’s eligible and non-eligible to ACOSOG-Z0011 trial. No significant differences in patient’s and tumor characteristics and treatment delivered were observed between the two arms. Higher positive-NSN rate was observed for patients with AC performed after ALND (17.65% for SN micro-metastases, 35.22% for SN macro-metastases) in comparison with AC administered before ALND.Gilles HouvenaeghelMonique CohenPédro RaroJérémy De TroyerPierre GimberguesChristine Tunon de LaraVivien CeccatoVéronique Vaini-CowenChristelle Faure-VirelizierFrédéric MarchalTristan GauthierEva JouvePierrick TheretClaudia RegisPhilippe GabelleJulia PernautFrancesco Del PianoGauthier D’HalluinStéphane LantheaumeEmile DaraiBassoodéo BeedassyCaroline Dhainaut-SpeyerXavier MartinSophie GirardRichard VilletEmilie MonrigalThéophile HoyekJean-François Le BrunPierre-Emmanuel ColomboAgnès TalletJean-Marie BoherSERC trial groupNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Gilles Houvenaeghel Monique Cohen Pédro Raro Jérémy De Troyer Pierre Gimbergues Christine Tunon de Lara Vivien Ceccato Véronique Vaini-Cowen Christelle Faure-Virelizier Frédéric Marchal Tristan Gauthier Eva Jouve Pierrick Theret Claudia Regis Philippe Gabelle Julia Pernaut Francesco Del Piano Gauthier D’Halluin Stéphane Lantheaume Emile Darai Bassoodéo Beedassy Caroline Dhainaut-Speyer Xavier Martin Sophie Girard Richard Villet Emilie Monrigal Théophile Hoyek Jean-François Le Brun Pierre-Emmanuel Colombo Agnès Tallet Jean-Marie Boher SERC trial group Sentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized SERC trial |
| description |
Abstract Based on results of clinical trials, completion ALND (cALND) is frequently not performed for patients with breast conservation therapy and one or two involved sentinel nodes (SN) by micro- or macro-metastases. However, there were limitations despite a conclusion of non-inferiority for cALND omission. No trial had included patients with SN macro-metastases and total mastectomy or with >2 SN macro-metastases. The aim of the study was too analyze treatment delivered and pathologic results of patients included in SERC trial. SERC trial is a multicenter randomized non-inferiority phase-3 trial comparing no cALND with cALND in cT0-1-2, cN0 patients with SN ITC (isolated tumor cells) or micro-metastases or macro-metastases, mastectomy or breast conservative surgery. We randomized 1855 patients, 929 to receive cALND and 926 SLNB alone. No significant differences in patient’s and tumor characteristics, type of surgery, and adjuvant chemotherapy (AC) were observed between the two arms. Rates of involved SN nodes by ITC, micro-metastases, and macro-metastases were 5.91%, 28.12%, and 65.97%, respectively, without significant difference between two arms for all criteria. In multivariate analysis, two factors were associated with higher positive non-SN rate: no AC versus AC administered after ALND (OR = 3.32, p < 0.0001) and >2 involved SN versus ≤2 (OR = 3.45, p = 0.0258). Crude rates of positive NSN were 17.62% (74/420) and 26.45% (73/276) for patient’s eligible and non-eligible to ACOSOG-Z0011 trial. No significant differences in patient’s and tumor characteristics and treatment delivered were observed between the two arms. Higher positive-NSN rate was observed for patients with AC performed after ALND (17.65% for SN micro-metastases, 35.22% for SN macro-metastases) in comparison with AC administered before ALND. |
| format |
article |
| author |
Gilles Houvenaeghel Monique Cohen Pédro Raro Jérémy De Troyer Pierre Gimbergues Christine Tunon de Lara Vivien Ceccato Véronique Vaini-Cowen Christelle Faure-Virelizier Frédéric Marchal Tristan Gauthier Eva Jouve Pierrick Theret Claudia Regis Philippe Gabelle Julia Pernaut Francesco Del Piano Gauthier D’Halluin Stéphane Lantheaume Emile Darai Bassoodéo Beedassy Caroline Dhainaut-Speyer Xavier Martin Sophie Girard Richard Villet Emilie Monrigal Théophile Hoyek Jean-François Le Brun Pierre-Emmanuel Colombo Agnès Tallet Jean-Marie Boher SERC trial group |
| author_facet |
Gilles Houvenaeghel Monique Cohen Pédro Raro Jérémy De Troyer Pierre Gimbergues Christine Tunon de Lara Vivien Ceccato Véronique Vaini-Cowen Christelle Faure-Virelizier Frédéric Marchal Tristan Gauthier Eva Jouve Pierrick Theret Claudia Regis Philippe Gabelle Julia Pernaut Francesco Del Piano Gauthier D’Halluin Stéphane Lantheaume Emile Darai Bassoodéo Beedassy Caroline Dhainaut-Speyer Xavier Martin Sophie Girard Richard Villet Emilie Monrigal Théophile Hoyek Jean-François Le Brun Pierre-Emmanuel Colombo Agnès Tallet Jean-Marie Boher SERC trial group |
| author_sort |
Gilles Houvenaeghel |
| title |
Sentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized SERC trial |
| title_short |
Sentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized SERC trial |
| title_full |
Sentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized SERC trial |
| title_fullStr |
Sentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized SERC trial |
| title_full_unstemmed |
Sentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized SERC trial |
| title_sort |
sentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized serc trial |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/c13f72211bf3423f91ce4844474dd13c |
| work_keys_str_mv |
AT gilleshouvenaeghel sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT moniquecohen sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT pedroraro sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT jeremydetroyer sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT pierregimbergues sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT christinetunondelara sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT vivienceccato sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT veroniquevainicowen sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT christellefaurevirelizier sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT fredericmarchal sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT tristangauthier sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT evajouve sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT pierricktheret sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT claudiaregis sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT philippegabelle sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT juliapernaut sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT francescodelpiano sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT gauthierdhalluin sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT stephanelantheaume sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT emiledarai sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT bassoodeobeedassy sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT carolinedhainautspeyer sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT xaviermartin sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT sophiegirard sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT richardvillet sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT emiliemonrigal sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT theophilehoyek sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT jeanfrancoislebrun sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT pierreemmanuelcolombo sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT agnestallet sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT jeanmarieboher sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial AT serctrialgroup sentinelnodeinvolvementwithorwithoutcompletionaxillarylymphnodedissectiontreatmentandpathologicresultsofrandomizedserctrial |
| _version_ |
1718378952657993728 |